| Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Sep'13 | |
|---|---|---|---|---|---|---|
CASH FLOWS FROM OPERATING ACTIVITIES: | ||||||
Net loss | ||||||
-28,372 | -35,489 | -15,003 | -10,097 | -22,380 | -5,573 | |
Adjustments to reconcile net loss to net cash used in operating activities: | ||||||
Acquired in-process research and development | ||||||
- | - | - | - | 17,459 | - | |
Depreciation and amortization expense | ||||||
1,110 | 1,176 | 564 | 530 | 221 | 95 | |
Stock-based compensation | ||||||
4,444 | 4,797 | 3,625 | 1,814 | 704 | 441 | |
Common stock issued to a supplier for services | ||||||
- | - | - | - | 0 | - | |
Amortization of intangible assets | ||||||
2,686 | 2,686 | 2,686 | 4,789 | 725 | - | |
Realized loss on sale of available-for-sale securities | ||||||
-508 | 0 | 0 | - | - | - | |
Amortization of prepaid rent | ||||||
0 | 0 | 85 | 85 | 85 | - | |
Gain on sale of equipment, net | ||||||
- | - | - | - | 2 | - | |
Deferred income tax benefit | ||||||
0 | -2,325 | -7,252 | -7,376 | -3,281 | - | |
Common stock issued for services in lieu of cash | ||||||
1,151 | 922 | 486 | 0 | - | - | |
Gain from change in fair value of warrant liability | ||||||
5,908 | -3,108 | 0 | 0 | - | - | |
Distribution of Asterias warrants to shareholders other than BioTime, Inc. | ||||||
-2,042 | -5,285 | 0 | 0 | - | - | |
Loss on disposal of property, plant, and equipment | ||||||
-112 | 0 | 0 | - | - | - | |
Gain on sale of equipment and furniture | ||||||
- | - | - | - | - | 2 | |
Changes in operating assets and liabilities: | ||||||
Grant receivable | ||||||
0 | 0 | -118 | 118 | 0 | - | |
Prepaid expenses and other current assets | ||||||
-13 | 887 | 680 | 182 | 423 | 222 | |
Other assets | ||||||
-846 | -10 | 95 | 0 | 0 | - | |
Accounts payable | ||||||
-675 | 329 | -24 | 120 | 567 | - | |
Accounts payable, accrued expenses and other current liabilities | ||||||
- | - | - | - | - | 353 | |
Accrued expenses | ||||||
62 | 1,863 | 584 | 199 | 96 | 234 | |
Deferred rent | ||||||
50 | 87 | 85 | 94 | - | - | |
Deferred rent liability | ||||||
- | - | - | - | 0 | - | |
Deferred grant income | ||||||
-2,185 | -328 | 2,513 | 0 | - | - | |
Deferred grant income | ||||||
- | - | - | - | 0 | - | |
Amount due to BioTime | ||||||
-321 | -242 | -85 | -1,449 | - | - | |
Amount due to parent, BioTime, Inc. | ||||||
- | - | - | - | 4,902 | 6,392 | |
Net cash used in operating activities | ||||||
- | - | - | -11,591 | -1,327 | - | |
Net cash used in operating activities | ||||||
-24,437 | -19,008 | -12,393 | - | - | -4,673 | |
CASH FLOWS FROM INVESTING ACTIVITIES: | ||||||
Purchase of property, plant and equipment | ||||||
290 | 894 | 313 | 115 | 1,247 | 1,600 | |
Proceeds from sale of common shares in public offering | ||||||
10,400 | 14,014 | 5,500 | - | - | - | |
Payment of security deposits | ||||||
- | - | - | - | 55 | 54 | |
Payments on construction in progress | ||||||
0 | 0 | 4,279 | 219 | 0 | - | |
Proceeds from sale of equipment and furniture | ||||||
- | - | - | - | 28 | 27 | |
Proceeds from the sale of available-for-sale securities | ||||||
1,012 | 0 | 0 | 12,661 | 0 | - | |
Reimbursement (payment) of security deposit, net | ||||||
0 | -31 | 1 | 307 | - | - | |
Net cash provided by investing activities | ||||||
722 | -863 | -4,593 | - | - | -1,627 | |
CASH FLOWS FROM FINANCING ACTIVITIES: | ||||||
Financing costs for sale of common stock and warrants | ||||||
- | - | - | - | 0 | - | |
Net cash provided by/(used in) investing activities | ||||||
- | - | - | 12,020 | -1,274 | - | |
Proceeds from sale of common stock under at-the-market transactions | ||||||
8,002 | 7,969 | 4,839 | 0 | - | - | |
Financing costs for at-the-market sales | ||||||
238 | 328 | 157 | 0 | - | - | |
Proceeds from sale of common shares in public offering | ||||||
- | - | - | 468 | - | - | |
Proceeds allocated to warrants classified as liabilities | ||||||
0 | 6,009 | 0 | 0 | - | - | |
Proceeds from sale of common shares | ||||||
- | - | - | - | 0 | - | |
Proceeds from sale of common stock and warrants | ||||||
- | - | - | - | 5,000 | - | |
Proceeds from exercise of warrants | ||||||
5 | 651 | 11,700 | 0 | 0 | - | |
Financing costs for sale of common stock in public offering | ||||||
517 | 1,275 | 508 | 0 | - | - | |
Financing costs allocated to warrants classified as liabilities | ||||||
0 | 550 | 0 | 0 | - | - | |
Proceeds from exercise of stock options | ||||||
18 | 2,026 | 29 | 8 | 0 | - | |
Repayment of lease liability and capital lease obligation | ||||||
489 | 427 | 1 | 0 | 0 | - | |
Shares retired to pay for employees' taxes | ||||||
0 | 168 | 98 | 0 | - | - | |
Reimbursement from landlord on construction in progress | ||||||
0 | 567 | 3,789 | 0 | 0 | - | |
Shares retired to pay for employees' taxes | ||||||
- | - | - | - | 0 | - | |
Payment to Geron in connection with acquisition of assets on October 1, 2013 | ||||||
- | - | - | - | 228 | - | |
Net cash provided by financing activities | ||||||
- | - | - | 476 | 4,772 | - | |
Net cash provided by financing activities | ||||||
17,181 | 28,488 | 25,093 | - | - | 6,392 | |
CASH, CASH EQUIVALENTS AND RESTRICTED CASH: | ||||||
NET DECREASE IN CASH AND CASH EQUIVALENTS | ||||||
-6,534 | 8,617 | 8,107 | 905 | 2,171 | - | |
OncoCyte common stock received as a dividend in kind from BioTime, net of taxes | ||||||
0 | 0 | 1,117 | 0 | 0 | - | |
Purchase of equipment and furniture, contributed by BioTime | ||||||
- | - | - | - | 459 | - | |
Construction in progress in accounts payable and accrued expenses | ||||||
- | - | - | 186 | 0 | - | |
Landlord receivable | ||||||
0 | 0 | -189 | -378 | 0 | - | |
Lease liability | ||||||
0 | 0 | 189 | 378 | 0 | - | |
Cross-License and Share Transfer with BioTime Inc., net | ||||||
0 | 415 | 0 | 0 | - | - | |
Available-for-sale BioTime securities contributed by BioTime | ||||||
- | - | - | - | 34,985 | - | |
Cancellation of indebtedness to BioTime | ||||||
- | - | - | - | 5,000 | - | |
Transaction costs paid by parent, on behalf of the Company | ||||||
- | - | - | - | 300 | - | |
Intangible assets acquired from Geron | ||||||
- | - | - | - | 29,017 | - | |
Adjustment to deferred tax liability arising from difference in book versus tax basis on Geron intangible assets acquired | ||||||
- | - | - | - | 11,558 | - | |
Investment in affiliates, contributed by BioTime | ||||||
- | - | - | - | 416 | - | |
Common stock and common stock warrants issued to BioTime and Geron in connection with acquisition and transfer of assets | ||||||
- | - | - | - | 74,098 | - | |
Common stock issued upon investment by BioTime | ||||||
- | - | - | - | - | 50 | |
Reduction of subscriptions receivable | ||||||
- | - | - | - | -50 | - | |
Common stock issued in exchange for non-cash consideration in connection with investment by officer | ||||||
- | - | - | - | - | 1 | |